Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 18, Issue 17, 2000, Pages 3093-3100

  Gordon, Alan N ^a   Granai, C O ^a   Rose, Peter G ^a   Hainsworth, John ^a   Lopez, Ana ^a   Weissman, Charles ^a   Rosales, Rosemary ^a   Sharpington, Timothy ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; DOXORUBICIN LIPID COMPLEX; LIPOSOME; MITOMYCIN; NITROSOUREA; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COATING; DYSESTHESIA; EDEMA; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; REFRACTORY PERIOD; STOMATITIS; TREATMENT OUTCOME;

EID: 0033850066     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.17.3093     Document Type: Article

References (21)

1. Cancer statistics, 1999
2. Epithelial ovarian cancer
3. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
4. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
5. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
6. Prolonged oral etoposide as second line therapy for platinum-resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study
7. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel
8. Impact of doxorubicin on survival in advanced ovarian cancer
9. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian cancer: A Gynecologic Oncology Group study
10. Randomized comparison of cisplatin with cyclophosphamide and cisplatin and cyclophosphamide with doxorubicin in advance ovarian cancer
11. A randomized study of cyclophosphamide and cisplatin with or without doxorubicin in advanced ovarian cancer
12. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer
13. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
14. A phase I clinical trial and pharmacokinetic evaluation of liposome encapsulated doxorubicin
15. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
16. Biodistribution and pharmacokinetics of IN-111 labeled Stealth liposomes in patients with solid tumors
17. Stealth liposomal doxorubicin (Doxil) delivers more doxorubicin to AIDS-Kaposi's sarcoma lesions than to normal skin
18. Liposomal doxorubicin (Doxil): Antitumor activity and unique toxicities during two complementary phase I studies
19. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
20. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish intergroup trial
21. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer